Bilastine
Sponsors
Faes Farma, S.A., Charite University, Berlin, Germany, Yuhan Corporation, Grupo de Alergología Clínica y Experimental, Universidade do Sul de Santa Catarina
Conditions
Allergic ConjunctivitisAllergic RhinitisAllergic RhinoconjunctivitisChronic UrticariaCold Contact UrticariaHay FeverHealthyHypersensitivity
Phase 1
A Randomized, Multiple Dose, Double Blind, 5-way Crossover Study of the Electrocardiographic (ECG) Effects of Bilastine
CompletedNCT00419783
Start: 2006-08-31End: 2006-12-31Updated: 2012-04-05
A Randomized, Multiple Dose, Double Blind, 5-way Crossover Study of the Electrocardiographic (ECG) Effects of Bilastine
CompletedNCT00419783
Start: 2006-08-31End: 2006-12-31Updated: 2012-04-05
Pharmacokinetic Study of Bilastine in Children From 2 to < 12 Years of Age With Either Allergic Rhinoconjunctivitis (AR) or Chronic Urticaria (CU)
CompletedNCT01081574
Start: 2010-01-31End: 2012-06-30Updated: 2012-09-26
Oral Bioavailability of Bilastine
CompletedNCT01124123
Start: 2010-05-31End: 2010-09-30Updated: 2012-09-26
Phase 2
A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of Bilastine in the Vienna Challenge Chamber
CompletedNCT00420082
Start: 2006-10-31End: 2006-12-31Updated: 2012-04-05
PK/PD and Steady State Efficacy Study of Bilastine Compared With Placebo Given Orally in the Treatment of the Symptoms of SAR in an EEC Model (5-arm)
CompletedNCT00574210
Start: 2007-10-31End: 2008-02-29Updated: 2019-02-15
Efficacy, Safety and PK of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo in the Symptomatic Treatment of SAR
CompletedNCT00574379
Start: 2007-12-31End: 2008-03-31Updated: 2019-02-15
Bilastine Updosing - Characterization of Underlying Mechanisms
CompletedNCT01271075
Start: 2010-09-30End: 2011-12-31Updated: 2012-05-31
Phase 3
Efficacy Study for the Symptomatic Treatment of Chronic Idiopathic Urticaria
CompletedNCT00421109
Start: 2006-07-31End: 2007-07-31Updated: 2012-04-05
Efficacy Study for the Symptomatic Treatment of Seasonal Allergic Rhinitis
CompletedNCT00504933
Start: 2005-05-31End: 2005-11-30Updated: 2012-04-05
A Phase III Efficacy Study of the Symptomatic Treatment of Seasonal Allergic Rhinitis With Bilastine
CompletedNCT01108783
Start: 2003-04-30End: 2004-02-29Updated: 2012-04-05
Efficacy Study for the Symptomatic Treatment of Perennial Allergic Rhinitis With a 1 Year Safety Extension
CompletedNCT01127620
Start: 2004-05-31End: 2006-11-30Updated: 2012-09-26
Investigate the Safety/Tolerability and Efficacy of Bilastine 20mg in Korean Patients With Seasonal Allergic Rhinitis
CompletedNCT01400828
Start: 2011-06-30End: 2014-05-31Updated: 2014-07-10
Bilastine Updosing in Chronic Spontaneous Urticaria
CompletedNCT02213367
Start: 2014-07-31End: 2016-03-31Updated: 2016-08-26
Study to Assess the Safety, Tolerability and Efficacy of Bilastine Ophthalmic Solution 0.6% in Children
CompletedNCT04810390
Start: 2021-03-26End: 2022-11-30Updated: 2023-03-16
Phase 4
Evaluation of the Inhibitory Effect of 5 Anti-Histamines in Urticaria
CompletedNCT01940393
Start: 2013-08-31End: 2014-01-31Updated: 2014-02-19
Quality of Life in Patients With Allergic Rhinitis: Clinical Trial With Bilastine or Loratadine
CompletedNCT02513290
Start: 2013-08-31End: 2014-08-31Updated: 2018-05-07
Effects of Bilastine on F1 Simulator Driving Performance in Patients Affected by Allergic Rhinitis and/or Urticaria
CompletedNCT02576041
Start: 2015-10-31End: 2015-12-31Updated: 2017-04-18